Connie Coulomb

Connie Coulomb is a highly experienced professional with a solid background in the biopharmaceutical industry, boasting 25 years of expertise in general management, strategy, and commercialization across large, medium, and small biopharma companies.

She has a rich history of working and consulting for renowned companies such as Amgen, Merck, Onyx, Biogen, Pfizer, Genentech, and Gilead, where she contributed her skills to various therapeutic areas including oncology, hematology, rare diseases, cardio-metabolic, neurology, autoimmune diseases, and biosimilars.

Connie is the founder of Coulomb Strategy Consulting LLC, a firm committed to elevating companies' strategies and maximizing commercial prospects. Previously, as Vice-president of BioPharma Capital, LLC, she specialized in advising on strategic collaborations and financial transactions within the life sciences sector.

Her noteworthy roles include serving as Divisional Vice-President and General Manager for Biogen, overseeing a $1.5B Multiple Sclerosis Business in the United States. At Amgen, she led a 150-people team for the Repatha launch, directed Commercial Operations for the Intercontinental division, managed the Oncology Marketing team, and played a pivotal role in acquisition evaluations and due diligence procedures.

With a strong academic foundation, Connie holds degrees in Business Administration and Accounting from the University of Buenos Aires, graduating with honors as Magna Cum Laude. She furthered her education by completing an MBA at the prestigious Stanford University.

In addition to her professional pursuits, she has co-authored the Global Guide to Compassionate Use programs in 2020, showcasing her commitment to industry-wide knowledge sharing and innovation.